Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.
| Publication Type | Academic Article |
| Authors | Perez K, Del Rivero J, Kennedy E, Basu S, Chauhan A, Connolly H, Dasari A, Gangi A, Clarke C, Hallet J, Howe J, Grady E, Ivanidze J, Mittra E, White S, Raj N, Vijayvergia N, Lewis M, Chan J, Kunz P, Mailman J, Arshad J, Soares H, Singh S, Chandrasekharan C, Soulen M, Janson E, Halfdanarson T, Strosberg J, Bergsland E |
| Journal | JCO Oncol Pract |
| Pagination | OP2500133 |
| Date Published | 05/09/2025 |
| ISSN | 2688-1535 |
| Abstract | PURPOSE: To develop a clinical practice guideline and recommendations for symptom management of patients with well-differentiated grade 1 to grade 3 metastatic gastroenteropancreatic neuroendocrine tumors. METHODS: ASCO convened an Expert Panel to develop a clinical practice guideline by reviewing the literature for relevant guidelines, systematic reviews, randomized controlled trials (RCTs), and observational studies to develop recommendations for clinical practice. RESULTS: The literature review identified eight guidelines, 19 systematic reviews, and three RCTs that informed the development of guideline recommendations. RECOMMENDATIONS: Recommendations are included for carcinoid syndrome, carcinoid heart disease and carcinoid crisis, and functional pancreatic neuroendocrine tumor syndromes. Recommendations are provided for surgical management, liver-directed therapy, and systemic therapy options, as well as palliative care. Limited guidance is provided for sequencing of interventions.Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines. |
| DOI | 10.1200/OP-25-00133 |
| PubMed ID | 40344544 |